When is systemic antiviral therapy indicated?

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

The development and clinical testing of systemic antiviral agents has been progressing rapidly in recent years. This has resulted in new applications for vidarabine, an agent originally released for systemic therapy solely in herpes simplex encephalitis, and the advent of intravenous acyclovir for certain herpes virus infections.

Original languageEnglish (US)
Pages (from-to)19-21
Number of pages3
JournalInternational Journal of Dermatology
Volume22
Issue number1
StatePublished - 1983
Externally publishedYes

Fingerprint

Vidarabine
Herpes Simplex Encephalitis
Acyclovir
Virus Diseases
Antiviral Agents
Therapeutics

ASJC Scopus subject areas

  • Dermatology

Cite this

When is systemic antiviral therapy indicated? / Chou, Sunwen.

In: International Journal of Dermatology, Vol. 22, No. 1, 1983, p. 19-21.

Research output: Contribution to journalArticle

@article{f8481019460248d7a6f2c39d04701cf7,
title = "When is systemic antiviral therapy indicated?",
abstract = "The development and clinical testing of systemic antiviral agents has been progressing rapidly in recent years. This has resulted in new applications for vidarabine, an agent originally released for systemic therapy solely in herpes simplex encephalitis, and the advent of intravenous acyclovir for certain herpes virus infections.",
author = "Sunwen Chou",
year = "1983",
language = "English (US)",
volume = "22",
pages = "19--21",
journal = "International Journal of Dermatology",
issn = "0011-9059",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - When is systemic antiviral therapy indicated?

AU - Chou, Sunwen

PY - 1983

Y1 - 1983

N2 - The development and clinical testing of systemic antiviral agents has been progressing rapidly in recent years. This has resulted in new applications for vidarabine, an agent originally released for systemic therapy solely in herpes simplex encephalitis, and the advent of intravenous acyclovir for certain herpes virus infections.

AB - The development and clinical testing of systemic antiviral agents has been progressing rapidly in recent years. This has resulted in new applications for vidarabine, an agent originally released for systemic therapy solely in herpes simplex encephalitis, and the advent of intravenous acyclovir for certain herpes virus infections.

UR - http://www.scopus.com/inward/record.url?scp=0020677937&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0020677937&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 19

EP - 21

JO - International Journal of Dermatology

JF - International Journal of Dermatology

SN - 0011-9059

IS - 1

ER -